ALTIMI - Trademark Details
Status: 602 - Abandoned-Failure To Respond Or Late Response
Serial Number
88304845
Word Mark
ALTIMI
Status
602 - Abandoned-Failure To Respond Or Late Response
Status Date
2021-09-19
Filing Date
2019-02-17
Mark Drawing
4000 - Standard character mark
Typeset
Published for Opposition Date
2020-12-15
Law Office Assigned Location Code
M50
Employee Name
BECHHOFER, YOCHEVED D
Statements
Goods and Services
House mark for a full line of pharmaceuticals and pharmaceutical preparations, namely, pharmaceutical preparations and substances used for the treatment of bone, joint, vertebral column, intestine, colon, skin, lung, eye, breast, ovary, cervix, stomach, bladder, kidney, head, brain, neck, and blood diseases and disorders; pharmaceutical preparations and substances for the treatment of autoimmune, immune system, inflammatory, inflammatory bowel, gastrointestinal, genitourinary, musculoskeletal, dermatological, pulmonary, respiratory, oncological, hepatological, lymphomas, leukemias, ophthalmic, transplant rejection, cardiovascular, endocrine, neurological, sleep, muscular, and psychiatric diseases and disorders;pharmaceutical preparations and substances used for the treatment of arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, juvenile idiopathic arthritis, enthesitis related arthritis, osteoarthritis, peripheral spondyloarthritis, polymyalgia rheumatic, spondyloarthropathies, acute disc prolapse, inflammatory bowel disease, Crohn's disease, ulcerative colitis, Intestinal Behçet's Disease, chronic pouchitis, small bowel lesions, Hermansky-Pudlak syndrome, autoimmune pancreatitis, multiple myeloma, multiple sclerosis, systemic lupus erythematosus, lupus nephritis, chronic inflammatory demyelinating polyneuropathy, autoimmune anemia, autoimmune hemolytic anemia, pure red cell aplasia, idiopathic thrombocytopenic purpura, Evans syndrome, type 1 diabetes mellitus, Sjogren's syndrome, encephalitis, IgG4-related disease, Devic's disease, myositis, psoriasis, psoriasis vulgaris, psoriasis arthropica, plaque psoriasis, palmoplantar psoriasis, hidradenitis suppurativa, bullous skin disorder, pemphigus, pemphigoid, kawasaki disease, interstitial cystitis, sleep apnea, sarcoidosis, retinal vascular disorders, age-related macular degeneration, refractory diabetic macular edema, uveitis, childhood uveitis, uveitic macular edema, choroidal neovascularization, Graves' ophthalmopathy, pyoderma gangrenosum, giant cell arteritis, Netherton syndrome, anaplastic thyroid cancer, breast cancer, ovarian cancer, cervical cancer, gastric cancer, colorectal cancer, non-squamous non-small cell lung cancer, glioblastoma, renal cell carcinoma, head and neck cancer, Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, lymphocyte predominant subtype of Hodgkin's Lymphoma, vasculitis, granulomatosis with polyangiitis, microscopic polyangiitis, graft-versus-host disease, graft-versus-host disease following allogenic hematopoietic stem cell transplantation, graft-versus-host disease following keratoprosthesis, kidney transplant, asthma, chronic fatigue syndrome, major depression, and bipolar depression
Classification Information
International Class
005 - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes
005, 006, 018, 044, 046, 051, 052
Class Status Code
6 - Active
Class Status Date
2019-03-10
Primary Code
005
First Use Anywhere Date
2020-07-01
First Use In Commerce Date
2020-07-01
Correspondences
Name
Altimi Biosciences, Inc.
Address
Please log in with your Justia account to see this address.
Trademark Events
Event Date | Event Description |
2019-02-20 | NEW APPLICATION ENTERED IN TRAM |
2019-03-10 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
2019-04-29 | ASSIGNED TO EXAMINER |
2019-04-29 | SUSPENSION LETTER WRITTEN |
2019-04-29 | LETTER OF SUSPENSION E-MAILED |
2019-04-29 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
2019-11-03 | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED |
2020-05-10 | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED |
2020-11-10 | APPROVED FOR PUB - PRINCIPAL REGISTER |
2020-11-25 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
2020-12-15 | PUBLISHED FOR OPPOSITION |
2020-12-15 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
2021-02-09 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
2021-02-10 | TEAS STATEMENT OF USE RECEIVED |
2021-03-01 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
2021-02-10 | USE AMENDMENT FILED |
2021-03-02 | STATEMENT OF USE PROCESSING COMPLETE |
2021-03-07 | SU - NON-FINAL ACTION - WRITTEN |
2021-03-07 | NON-FINAL ACTION E-MAILED |
2021-03-07 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
2021-09-19 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE |
2021-09-20 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND |